Ginkgo Bioworks raises $100M

What does Ginkgo Bioworks do?
Ginkgo Bioworks, is an organism design company. The company designs custom microbes for customers across multiple markets.The company is built to scale organism engineering process using hardware and software automation. Organism engineers at this design company learn from nature to develop new organisms which replace technology with biology.
How much Ginkgo Bioworks was funded?
Ginkgo raised $100M in Series C on June 8, 2016 from Allen & Company, Baillie Gifford, Viking Global Investors, Senator Investment Group, Cascade Investment and Continuity Fund.
Previous funding
$120k on July 16, 2014 from Y Combinator, Farzad (Zod) Nazem, TEEC Angel Fund, David Spector, CRCM Venture Capital and Eleven Two Capital
$9M in Series A on March 18, 2015 from Felicis Ventures, Data Collective, OS Fund, Vast Ventures, David Beyer, iGlobe Partners and Ken Arnold.
$45M in Series B on July 23, 2015 from OS Fund, Viking Global Investors, Felicis Ventures and Eleven Two Capital.
What is next for Ginkgo Bioworks?
With the latest funding the company has raised a total of $154 M. The company plans to use the latets funding raised for fuelling the company’s growth into new markets, such as human health markets, industrial enzymes and commodity chemicals. The funding will also be used for building next gen automated foundry, Bioworks2, where the company’s organism engineers develop new designs on a larger scale. The company has also announced its partnership with Gen9 and TwistBioscience, the leading providers of Synthetic DNA, to have 600 M base pairs of DNA manufactured, which will serve as raw material for the company’s biological prototypes and will be used for generating genetic designs which will be built and tested in the company’s Bioworks2, new foundry.
More about Ginkgo Bioworks
The company was founded in 2008 by Jason Kelly and Reshma Shetty. It has its headquarters in Boston, MA.